P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer

References

• Aoyama T., Gelboin V., Gonzalez F. Mutagenic activation of 2‐amino‐3‐methylimidazo(4,5‐f)‐quinoline by complementary DNA expressed human liver cytochromes P450. Cancer Research 1990; 50: 2034–2063
   Google Scholar
• Ayesh R., Idle J. R., Ritchie J. C., Crothers M. J., Hetzel M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (London) 1984; 312: 169–170
   PubMed Web of Science ®Google Scholar
• Back D. J., Tjia J. F., Karbwang J., Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. British Journal of Clinical Pharmacology 1988; 26: 23–29
   PubMed Web of Science ®Google Scholar
• Bartsch H., Petruzzelli S., De Flora S., Hietanen E., Camus A. ‐M., Castegnaro M., Geneste O., Camoirano A., Saracci R., Giuntini C. Carcinogen metabolism and DNA adducts in human lung tissues as affected by tobacco smoking or metabolic phenotype: a case control study on lung cancer patients. Mutation Research 1991; 250: 103–114
   PubMed Web of Science ®Google Scholar
• Brady J. F., Li D., Ishizaki H., Lee M., Ninxy S. M., Xisao F., Yang C. H. Induction of P4502E1 and P4502B1 by secondary ketones and the role of P4502E1 in chloroform metabolism. Toxicology and Applied Pharmacology 1989; 100: 342–349
   PubMed Web of Science ®Google Scholar
• Brady J. F., Li D., Ishizaki H., Yang C. S. Effect of disulfiram on hepatic P4502E1 and other microsomal enzymes and hepatotoxicity in rats. Toxicology and Applied Pharmacology 1991; 108: 366–373
   PubMed Web of Science ®Google Scholar
• Brain W. R., Sari M. A., Iwasaki M., Shimada T., Kaminski L. S., Guengerich F. P. Catalytic activities of human liver cytochrome P450 3A4 expressed in Saccharomyces cerevisiae. Biochemistry 1990; 29: 11280–11292
   PubMed Web of Science ®Google Scholar
• Brain W. R., Srivastava P. K., Umbenhauer D. R., Lloyd R. S., Guengerich F. P. Expression of a human liver cytochrome P450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 1989; 28: 4993–4999
   PubMedGoogle Scholar
• Butler M. ‐A., Iwasaki M., Guengerich F. P., Kadlubar F. F. Human, cytochrome P450PA, the phenacetine‐O‐deethylase is primarily responsible for the hepatic 3‐demethylation of caffeine and N‐oxidation of carcinogenic arylamines. Proceedings of the National Academy of Sciences. USA 1989; 86: 7696–7700
   PubMed Web of Science ®Google Scholar
• Burke M. D., Thomson S., Elcombe C. R., Halpert J., Haaparanta T., Mayer R. T. Ethoxy‐, penthoxy‐ and benzyloxy‐phenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P450. Biochemical Pharmacology 1985; 34: 3337–3345
   PubMed Web of Science ®Google Scholar
• Conney A. Induction of microsomal cytochrome P450 enzymes: the first Bernard Brodie award lecture in Pensylvania State University. Life Sciences 1986; 39: 2493–2518
   PubMed Web of Science ®Google Scholar
• Crespi C. L., Gonzalez F. J., Langenbach R., Gelboin H. V., Penman B. W. Stable expression of human P450 cDNAs in human lymphoblastoid cells. Journal of Basic and Clinical Physiology and Pharmacology 1992; 3: 19–29
   PubMedGoogle Scholar
• Crespi C. L., Penman B. W., Leaky J. A., Arlotto M. P., Stark A., Parkinson A., Turner T., Steimel D. Human cytochrome P450 1A3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to the nitrosamine activation by human cytochrome P4502E1. Carcinogenesis 1990; 3: 1293–1301
   Google Scholar
• Dannan G. A., Porubek D. J., Nelson S. D., Waxman D. J., Guengerich F. P. 17β‐Estradiol 2‐ and 4‐hydroxylation catalyzed by rat hepatic P450: roles of individual forms, inductive effects, developmental patterns and alternations by gonadectomy and hormone replacement. Endocrinology 1986; 118: 1952–1960
   PubMed Web of Science ®Google Scholar
• Dayer P., Laemann T., Pharm D., Striberni R. Dextramethorphan O‐demethylation in liver microsomes as a prototype reaction to monitor cytochrome db1 activity. Clinical Pharmacology and Therapy 1989; 45: 35–40
   Google Scholar
• Ekstrom G., Bahr C., Ingelman‐Sundberg M. Human Liver microsome P4502E1. Immunological evaluation of its contribution to microsomal ethanol oxidation, carbon tetrachloride reduction and NADPH oxidase activity. Biochemical Pharmacology 1989; 38: 689–693
   PubMed Web of Science ®Google Scholar
• Elshourbagy N. A., Guselian P. S. Separation and purification of a novel form of P450 from rats treated with pregnenolone 16α‐ carbonitrile. Journal of Biological Chemistry 1980; 255: 1279–1285
   PubMed Web of Science ®Google Scholar
• Feierman D. E., Cederbaum A. I. Inhibition of microsomal oxidation of ethanol by pyrazole and 4‐methyrpyrazole in vitro. Increased effectiveness after induction by pyrazole and 4‐methylpyrazole. Biochemical Journal 1986; 239: 671–677
   PubMed Web of Science ®Google Scholar
• Fleming G., Branch R. A., Wilkinson G. R., Guengerich F. P. Human liver N‐hydroxylation of dapsone by P4503A4. Molecular Pharmacology 1992; 41: 975–980
   PubMed Web of Science ®Google Scholar
• Fonne‐Pfister R., Meyer U. A. Xenobiotic and endobiotic inhibitors of cytochrome P450db1 function, the target of the debrizoquine‐sparteine type polymorphism. Biochemical Pharmacology 1988; 37: 3829–3835
   PubMed Web of Science ®Google Scholar
• Funae Y., Imaoka S. Simultaneous purification of multiple forms of rat liver microsomal P450 by HPLC. Biochimica et Biophisica Act 1985; 842: 119–132
   PubMed Web of Science ®Google Scholar
• Funae Y., Imaoka S. Purification and characterization of liver microsomal P450 from untreated male rats. Biochimica et Biophisica Acta 1987; 926: 349–358
   PubMed Web of Science ®Google Scholar
• Ged C., Ronillon J. M., Pichard L., Combalbert J., Bressot N., Bories P., Michel H., Beaunne P., Maurel P. The increase of urinary excression of 6β‐hydroxycortisol as a marker of human hepatic cytochrome P4503A induction. British Journal Clinical Pharmacology 1989; 28: 373–387
   PubMed Web of Science ®Google Scholar
• Ged C., Umbenhauer D. R., Bellew T. M., Bork R. W., Srivastava P. K., Shinriki N., Lloyd R. S., Guengerich F. P. Characterization of cDNAs, mRNAs and protein related to human liver microsomal P450‐S mephenytoin‐4'hydroxylase. Biochemistry 1988; 279: 6929–6940
   Google Scholar
• Godden P. M. M., Kass G., Mayer R. T., Burke M. D. The effects of cigarette smoke compared to 3‐methylhoianthrene and phenobarbitone on alkoxyresorufin metabolism by lung and liver microsomes from rats. Biochemical Pharmacology 1987; 36: 3393–3398
   PubMed Web of Science ®Google Scholar
• Goldstein J. A., Faletto M. B., Romkes‐Sparks M., Sullivan T., Kitareewan S., Raucy J. L., Lasker J. M., Ghanayem B. I. Evidence that CYP2C19 is the major (S)‐mephenytoin 4'‐hydroxylase in humans. Biochemistry 1994; 33: 1743–1752
   PubMed Web of Science ®Google Scholar
• Gonzalez F. The molecular biology of cytochrome P450. Pharmacological Reviews 1989; 40: 4–11
   Google Scholar
• Gonzalez F. Molecular genetics of the P450 superfamily. Pharmacology and Therapeutics 1990; 45: 1–31
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Analysis and characterization of enzymes. Principles and Methods of Toxicology2nd edn., A. W. Hayes. Raven, New York 1989; 1–29
   Google Scholar
• Guengerich F. P. Mechanism based inactivation of human liver microsomal P450IIIA4 by gestodene. Chemical Research in Toxicology 1990a; 3: 363–371
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Metabolism of 17α‐ethynylestradiol in humans. Life Sciences 1990b; 47: 1980–1981
   Google Scholar
• Guengerich F. P. Oxidation of sparteins by cytochrome P450: evidence against the formation of N‐oxides. Journal of Medicinal Chemistry 1984; 27: 1101–1103
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Brian W. R., Iwasaki M., Sari M. A., Baarnhielm C., Berntsson P. Oxidation of dihidropyridine calcium channel blockers and analogues by human liver cytochrome P450 3A4. Journal of Medicinal Chemistry 1991; 34: 1838–1844
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Dannan G. A., Wright S. T., Martin M. V., Kaminsky L. S. Purification and characterization of rat liver microsomal cytochromes P450: electrophoretic, spectral, catalytic and immunochemical properties and inducibility of 8 isozymes isolated from rats treated with phenobarbital or β‐naphtoflavone. Biochemistry 1982; 21: 6019–6030
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Distlerath L. M., Kelly P. E. B., Wolf T., Shimada T., Umbenbauer D. R., Martin M. V. Human Liver cytochromes involved in polymorphisms of drug oxidation. Xenobiotica 1986a; 16: 367–378
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Kim D. ‐H. In vitro inhibition of dihidropyridine oxidation and aflatoxin B1 oxidation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 1990; 11: 2275–2279
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Kim D. ‐H., Iwasaki M. Role of human P4502E1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology 1991; 4: 168–178
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Martin M., Beaune P. H., Kremers P., Wolf T., Waxman D. Characterization of rat and human microsomal P450 forms involved in the nifedipine oxidation—a prototype for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry 1986b; 261: 5051–5060
   PubMed Web of Science ®Google Scholar
• Hailang Z., Stewart J. T. Improved HPLC determination of chlorzoxazone and its hydroxymetabolite in human serum and urine. Analytical Letters 1993; 26: 675–687
   Google Scholar
• Halvorson M., Greenway D., Eberhart D., Fitzgerald K., Parkinson A. Reconstituion of testosterone oxidation by purified rat cytochrome P4503A1 (p). Archives of Biochemistry and Biophysics 1990; 227: 166–180
   Google Scholar
• Hammons G. J., Guengerich F. P., Weis C. C., Bfland F., Kadlubar F. F. Metabolic oxidation of carcinogenic arylamines by rat, dog and human hepatic microsomes and by purified flavin containing cytochrome P450 monooxygenases. Cancer Research 1985; 45: 3578–3585
   PubMed Web of Science ®Google Scholar
• Hanioka N., Kimura S., Meyer U. A., Gonzalez F. J. The human CYP2D lokus associated with a common genetic defect in drug oxidation: a G1934–a base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. American Journal of Human Genetetics 1990; 47: 994–1001
   PubMed Web of Science ®Google Scholar
• Harvison P., Guengerich F. P., Rashed M. S., Nelson S. D. Cytochrome P450 isozyme selectivity in the oxidation of acetaminophen. Chemical Research of Toxicology 1989; 1: 47–52
   Google Scholar
• Hunt C. M., Watkins P. B., Saenger P., Stave G. M., Barlascini N., Watlington C. O., Wright J. T., Guzelian P. S. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clinical Pharmacology and Therapeutics 1992; 51: 18–23
   PubMed Web of Science ®Google Scholar
• Imoka S., Enomoto K., Oda Y., Asada A., Fujimori M., Shimada T., Fujita S., Guengerich F. P., Funae Y. Lidocaine metabolism of human cytohrome P450s purified from hepatic microsomes: comparison with rat hepatic cytochrome P450s. Journal of Pharmacology and Experimental Therapeutics 1990; 255: 1385–1391
   PubMedGoogle Scholar
• Imoka S., Funae Y. Purification and characterization of six P450 from hepatic microsomes of immature female rats. Journal of Biochemistry 1987; 102: 843–851
   PubMedGoogle Scholar
• Ioannides C., Parke D. V. Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. Drug Metabolism Reviews 1993; 25: 485–501
   PubMed Web of Science ®Google Scholar
• Jansson I., Mole J., Schenkman J. B. Characterization of a new form (RLM2) of liver microsomal cytochrome P450 from untreated rats. Journal of Biological Chemistry 1985; 260: 7084–7093
   PubMed Web of Science ®Google Scholar
• Johansson I., Ingelman‐Sundberg M. Benzene metabolism by ethanol‐ acetone‐ and benzene inducible cytochrome P450 IIE1 in rat and rabbit liver microsomes. Cancer Research 1988; 48: 5387–5390
   PubMed Web of Science ®Google Scholar
• Kadlubar F. F., Guengerich F. P., Butler M. ‐A., Delclos K. B. Cytochromes P450 as determinants of susceptibility to carcinogenesis is by aromatic amines and nitroaromatic hydrocarbons. Chemical Carcinogenesis, F. Feo, P. Pani, A. Columbano, R. Garcea. Plenum Publishing Corporation, New York 1988; 17–23
   Google Scholar
• Kaisary A., Smith P., Jaczq P., McAllister E., Wilkinson G. R., Ray W. A., Branch R. A. Genetic predisposition to Bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factor. Cancer Research 1987; 47: 5488–5493
   PubMed Web of Science ®Google Scholar
• Kalow W., Tang B. ‐K. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clinical Pharmacology and Therapy 1991; 50: 508–519
   PubMed Web of Science ®Google Scholar
• Kamataki T., Maeda K., Yamazoe Y., Nagai T. S., Kato R. Sex differences of P450 in the rat: purification, characterization and quantitation of constitutive forms of P450 from liver microsomes of male and female rats. Archives of Biochemistry and Biophysics 1982; 225: 758–770
   Google Scholar
• Kamataki T., Yokoi T., Kitamura R., Sakuma T. Expression and characterization of human fetal liver cytochrome P450 (P4503A7). Journal of Basic and Clinical Physiology and Pharmacology 1992; 3: 20–21
   Google Scholar
• Kimura S., Umeno M., Skoda R. C., Meyer U. A., Gonzalez F. J. The human debrisoquine 4‐hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. American Journal of Human Genetics 1989; 45: 889–904
   PubMed Web of Science ®Google Scholar
• Knodell R., Browne D. G., Gwozdz G. P., Brian W. R., Guengerich F. P. Differential Inhibition of individual human liver P450 by cimetidine. Gastroenterology 1991; 101: 1680–1691
   PubMed Web of Science ®Google Scholar
• Knodell R. G., Dubey R. K., Wilkinson G. R., Guengerich F. P. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S‐mephemytoin 4‐hydroxylation. Journal of Pharmacology and Experimental Therapy 1989; 245: 845–849
   Web of Science ®Google Scholar
• Kronbach T., Fischer V., Meyer U. A. Cyclosporin metabolism in human liver. Identification of a cytochrome 3 gene family as the major cyclosporin metabolizing enzyme explains interactions of cyclosporin with other drugs. Clinical Pharmacology and Therapeutics 1989; 43: 630–635
   Google Scholar
• Larrey D., Distlerath L. M., Dannan G. A., Wilkinson G. R., Guengerich F. P. Purification and characterization of the rat liver microsomal P450 involved in the 4‐hydroxylation of debrizoquine, a prototype for the genetic variation in oxidative drug metabolism. Biochemistry 1984; 23: 2787–2795
   PubMed Web of Science ®Google Scholar
• Lasker J., Raucy J., Kubota S., Bloswick B. P., Black M., Lieber C. H. Purification and characterization of human liver cytochrome P450ALC. Biochemical and Biophysical Research Communications 1987; 148: 232–238
   PubMed Web of Science ®Google Scholar
• Leo M. A., Lasker J. M., Rancy J. L., Clim C. ‐L., Black M., Lieber C. S. Metabolism of retinol and retinolic acid by human liver cytochrome P4502C8. Archives of Biochemistry and Biophysics 1989; 269: 305–312
   PubMed Web of Science ®Google Scholar
• Lown K., Kolars J., Turgeon K., Merion R., Wrighton S., Watkins P. B. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clinical Pharmacology and Therapeutics 1992; 51: 229–238
   PubMed Web of Science ®Google Scholar
• McManus M., Burgess W. M., Veronese M. E., Huggett A., Quattrochi L. C., Turkey R. H. Metabolism of 2‐acetylaminofluorene and benzo(a)pyrene and activation of food derived heterocyclic amine mutagens by human cytochromes P450. Cancer Research 1990; 50: 3367–3376
   PubMed Web of Science ®Google Scholar
• Mehlman M. A. Dangerous properties of petroleum refining products: benzene—health effects. Ramazzini Newsletter 1991; 3: 16–20
   Google Scholar
• Mimura M., Baba T., Yamazaki H., Ohmori S., Inui Y., Gonzalez F. J., Guengerich F. P., Shimada T. Characterization of cytochrome 2B6 in human liver microsomes. Drug Metabolism and Disposition 1993; 21: 1048–1056
   PubMed Web of Science ®Google Scholar
• Miranda C., Reed R. L., Guengerich F. P., Buhler D. R. Role of P4503A4 in the metabolism of the pyrrazolidine alkaloid senecionine in human liver. Carcinogenesis 1991; 12: 512–519
   Google Scholar
• Mishin V., Ingelman‐Sundberg M. Metabolism of chlorzoxazone in rat brain. ISSX Proceedings 1992; 2: 95
   Google Scholar
• Morgan E., Macgeoch C., Gustafsson J. A. Sexual differentiation of cytochrome P450 in rat liver. Molecular Pharmacology 1985; 27: 471–479
   PubMed Web of Science ®Google Scholar
• Murray M., Reidy G. Selectivity in the inhibition of mammalian cytochromes P450 by chemical agents. Pharmacological Reviews 1990; 142: 85–101
   Google Scholar
• Nakajima T., Wang R. ‐S., Elovaara E., Park S. S., Gelboin H. V., Vainio H. A comparative study on the contribution of cytochrom P450 isozymes to metabolism of benzene, toluene and trichloroethylene in rat liver. Biochemical Pharmacology 1992; 43: 251–257
   PubMed Web of Science ®Google Scholar
• Narimatzu S., Watanabe K., Matsunaga T., Yamamoto I., Imaoka S., Funae Y., Yoshimura H. Cytochrome P450 isozymes involved in the metabolic activation of Δ‐tetrahydrocannabinol by rat liver microsomes. Drug Metabolism and Disposition 1990; 18: 943–948
   PubMedGoogle Scholar
• Nebert D. W., Nelson D. R., Adesnik M., Coon M. J., Estabrook R. W., Gonzalez F. J., Guengerich F. P., Gunsalus I. C., Johnson E. F., Kemper B., Levin W., Phillips W., Sato R., Waterman M. R. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 1989; 8: 1–13
   PubMedGoogle Scholar
• Nebert D. W., Nelson D. R., Coon M. J., Estabrook R. W., Feyereisen R., Kuriyama Y. F., Gonzalez F. J., Guengerich F. P., Gunsalus I. C., Johnson E. F., Loper J. C., Sato R., Waterman M. R., Waxman D. J. The P450 superfamily: update on new sequences, gene mapping and recommended literature. DNA and Cell Biology 1991; 10: 1–14
   PubMed Web of Science ®Google Scholar
• Nelson D. R., Kamataki T., Waxman D. J., Guengerich F. P., Estabrook R. W., Feyereisen R., Gonzalez F. J., Coon M. J., Gunsalus I. C., Gotoh O., Okuda K., Nebert D. W. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and Cell Biology, 12: 1–51
   PubMedGoogle Scholar
• Nouso K., Thorgeirsson S. S., Battula N. Stable expression of human P450IIE1 in mammalian cells: metabolic activation of nitroso dimethylamine and formation of adducts with cellular DNA. Cancer Research 1992; 52: 1796–1800
   PubMed Web of Science ®Google Scholar
• Ohnhaus E. E., Breckenridge A. M., Park B. K. Urinary excretion of 6β‐hydroxycortisol and the time course measurement of enzyme induction in man. European Journal of Clinical Pharmacology 1990; 36: 39–46
   Google Scholar
• Okey A. Enzyme induction in the cytochrome P450 system. Pharmacology and Therapeutics 1990; 45: 241–298
   PubMed Web of Science ®Google Scholar
• Otton S. V., Crewe H. K., Lennard M. S., Tucker G. T., Woods H. F. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 1989; 247: 242–247
   Google Scholar
• Palakodaty R. B., Clejan L. A., Krikun G., Feierman D. E., Cederbaum A. I. Characterization and identification of a pyrazole inducible form of cytochrome P450. Journal of Biological Chemistry 1989; 263: 878–884
   Google Scholar
• Park S. S., Waxman D. J., Miller H., Robinson R., Attisano C., Guengerich F. P., Gelboin H. V. Preparation and characterization of monoclonal antibodies to pregnenolone 16α carbonitrile inducible rat liver cytochrome P450. Biochemical Pharmacology 1986; 35: 2859–2867
   PubMed Web of Science ®Google Scholar
• Perruca E., Grunaldi R., Frigo G. M., Sardi A., Leonid H., Ohnhaus E. E. Comparative effects of rifabulin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Environmental Journal of Clinical Pharmacology 1988; 34: 595–599
   PubMedGoogle Scholar
• Peter R., Bocher R., Beaune P. H., Iwasaki M., Guengerich F. P., Yang C. S. Hydroxylation of chlorzoxazone as a specific probe for human liver P4502E1. Chemical Research Toxicology 1990; 3: 566–573
   PubMed Web of Science ®Google Scholar
• Robertson I. G. C., Zeiger E., Godstein J. A. Specifity of rat liver cytochrome P450 isozymes in the mutagenic activation of benzo(a)pyrene, aromatic amines and aflatoxin B1. Carcinogenesis 1983; 4: 93–96
   PubMed Web of Science ®Google Scholar
• Romkes M., Faletto M. B., Blaisdell J. A., Racy J. L., Goldstein J. A. Cloning and expression of complementary cDNAs for multiple members of the human cytochrome P450 IIC subfamily. Biochemistry 1991; 30: 3247–3255
   PubMed Web of Science ®Google Scholar
• Ryan D. E., Iida S., Wood A. W., Thomas P. E., Lieber C. S., Levin W. Characterization of three highly purified P450 from hepatic microsomes of adult male rats. Journal of Biological Chemistry 1984; 259: 1239–1250
   PubMed Web of Science ®Google Scholar
• Ryan D. E., Koop D. K., Thomas P. E., Coon M. J., Levin W. Evidence that izoniazid and ethanol induce the same microsomal P450 in rat liver, an isozyme homologous to rabbit liver P450 isozyme 3a. Archives of Biochemistry and Biophysics 1986; 246: 633–644
   PubMed Web of Science ®Google Scholar
• Ryan D., Levin W. Purification and characterisation of hepatic microsomal cytochrome P450. Pharmacology and Therapeutics 1990; 45: 153–239
   PubMed Web of Science ®Google Scholar
• Ryan D. E., Thomas P. E., Korzeniowski D., Levin W. Separation and characterization of highly purified forms of liver microsomal cytochrome P450 from rats treated with polychlorinated biphenyls phenobarbital, and 3‐methylcholanthrene. Journal of Biological Chemistry 1979; 254: 1365–1374
   PubMed Web of Science ®Google Scholar
• Ryan D. E., Thomas P. E., Reik L. M., Levin W. Purification, characterization and regulation of 5 rat hepatic microsomal cytochrome P450 enzymes. Xenobiotica 1982; 12: 727–747
   PubMed Web of Science ®Google Scholar
• Schellens H. M., Wart H. H., Hoevers J. W., Breimer D. D. GC determination of sparteine and 2‐ and 5‐dehydrosparteine in plasma and urine. Journal of Chromatography 1988; 431: 203–209
   PubMedGoogle Scholar
• Seidel S. L., Shires T. K. Purification of a previously unreported form of P448 from the liver of #‐methylcholantrene pretreated rat. Biochemical Journal 1986; 235: 859–868
   PubMed Web of Science ®Google Scholar
• Sesardic D., Boobis A. R., Edwards R. J., Davies D. S. A form of P450 in man, orthologous to form d in the rat catalyses the O‐deethylation of phenacetine and is inducible by cigarette smoking. British Journal of Clinical Pharmacology 1988; 26: 363–372
   PubMed Web of Science ®Google Scholar
• Sesardic D., Booris A. R., Murray B. P., Murray S., Segura J., de LA Torre R., Davies D. S. Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. British Journal of Clinical Pharmacology 1990; 29: 651–653
   PubMed Web of Science ®Google Scholar
• Schenkman J. B. Steroid metabolism by constitutive forms of P450. Journal of Steroid Biochemistry and Molecular Biology 1992; 43: 1023–1030
   PubMed Web of Science ®Google Scholar
• Shimada T., Guengerich F. P. Participation of a form of rat liver microsomal cytochrome P450 induced by pregnenolone 16α carbonitrile in the 4‐hydroxylation of mephenytoin, a prototype of genetic polymorphism of oxidative drug metabolism. Molecular Pharmacology 1985; 28: 215–221
   PubMed Web of Science ®Google Scholar
• Shimada T., Guengerich F. P. Evidence for the cytochrome P450NF, the nifedipine oxidase, being the principle enzyme involved in the bioactivation of aflatoxins in human liver. Proceedings of the National Academy of Sciences, USA 1987; 86: 462–465
   Google Scholar
• Shimada T., Guengerich F. P. Inactivation of 1·3‐, 1,6‐ and 1,8‐Dinitropyrene by P450 enzymes in human and rat liver microsomes. Cancer Research 1990; 50: 2036–2043
   PubMed Web of Science ®Google Scholar
• Shimada T., Iwasaki M., Martin M. V., Guengerich F. P. Human liver microsomal P450 enzymes involved in the bioactivation of procaracinogens detected by umu‐gene response in Salmonella typhimurium TA1535 pSK1002. Cancer Research 1989a; 49: 3218–3228
   PubMed Web of Science ®Google Scholar
• Shimada T., Martin M. V., Pruess–swartz P., Marnett L. J., Guengerich F. P. Roles of individual human P450 enzymes in the bioactivation of benzo(a)pyrene‐7,8‐dehidroxy‐7,8‐dihidro‐benzo(a)pyrene and other dihidrodiol derivatives of PAH. Cancer Research 1989b; 49: 6304–6312
   PubMed Web of Science ®Google Scholar
• Shimada T., Nakamura S. I. Cytochrome P450 mediated activation of procarcinogens and promutagens to DNA damaging products by measuring expression of umu‐gene in Salmonella typhimurium TA1535. Biochemical Pharmacology 1987; 36: 1979–1987
   PubMed Web of Science ®Google Scholar
• Shimada T., Nakamura S. I., Imaoka S., Funae Y. Genotoxic and mutagenic activation of aflatoxin B1 by constitutive forms of P450 in rat liver microsomes. Toxicology and Applied Pharmacology 1987; 91: 13–21
   PubMed Web of Science ®Google Scholar
• Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F. P. Interindividual variation in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 japanese and 30 caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Sinclair J. F., McCafrey J., Sinclair P. R., Bement W. J., Lambrecht L. K., Wood S. G., Smith L. E., Shenkman J. B., Guzelain P. S., Park S. S., Gelboin H. V. Ethanol increases cytochromes P4502E, 2B1/2 and 3A in cultured rat hepatocytes. Archives of Biochemistry and Biophysics 1991; 284: 360–365
   PubMedGoogle Scholar
• Snyderwine E., Battula N. Selective mutagenic activation by cytochrome P3450 of carcinogenic arylamines found in foods. Journal of the National Cancer Institute 1989; 81: 223–227
   PubMedGoogle Scholar
• Souc`ek P., Gut I. P450 in rat: structures, functions properties and relevant human forms. Xenobiotica 1992; 22: 83–103
   PubMedGoogle Scholar
• Speirs C. J., Murray S., Davies D. S., Biola Mabadeje A. F., Boobis A. R. Debrisoquine oxidation phenotype and susceptibility to lung cancer. British Journal Clinical Pharmacology 1990; 29: 101–109
   PubMed Web of Science ®Google Scholar
• Srivastava P. K., Yun C. ‐H., Beaune P. H., Ged C., Guengerich F. P. Separation of human liver microsomal tolbutamide hydroxylase and (S)‐mephenytoin 4'hydroxylase cytochrome P450 enzymes. Molecular Pharmacology 1991; 40: 69–79
   PubMed Web of Science ®Google Scholar
• Thomas P. E., Reik L. M., Ryan D. E., Levin W. Characterization of nine monoclonal antibodies against rat hepatic cytochrome P450. Journal of Biological Chemistry 1984; 259: 3890–3899
   PubMed Web of Science ®Google Scholar
• Wallin H., Mikalsen A., Guengerich F. P., Ingelman‐Sundberg M., Solberg K. E., Rossland J., Alexander J. Differential rates of metabolic activation and detoxication of the food mutagen 2‐amino‐6‐phenyl‐imidazo[4,5‐b]pyridine by different P450. Carcinogenesis 1980; 1: 489–492
   Google Scholar
• Waxman D. J., Attisano C., Guengerich F. P., Lapenson D. P. Human liver microsomal steroid metabolism: identification of the major microsome steroid hormone 6β‐hydroxylase cytochrome P450 enzyme. Archives of Biochemistry and Biophysics 1988; 263: 424–436
   PubMed Web of Science ®Google Scholar
• Waxman D. J., Light D. R., Walsh C. Rat hepatic cytochrome P450 isoenzyme 2c: identification as a male specific developmentally induced steroid 16α‐hydrolase and comparison to female specific cytochrome P450 enzyme. Journal of Biological Chemistry 1984; 259: 15481–15485
   PubMed Web of Science ®Google Scholar
• Waxman D. J., Walsh C. Cytochrome P450 isozyme 1 from phenobarbital induced rat liver: purification, characterization and interactions with metyrapone and cytochrome b5. Biochemistry 1983; 2: 4846–4855
   Google Scholar
• Wheeler C. W., Parks S. S., Guenthner T. M. Immunochemical analysis of cytochrome P4501A1 homologue in human lung microsomes. Molecular Pharmacology 1990; 38: 634–643
   PubMed Web of Science ®Google Scholar
• Williams D. E., Reed R., Kedzievski B., Dannan G., Guengerich F. P., Buhler R. Bioactivation and detoxification of the pyrrolizidine alkaloid senecionine by P450s in rat liver. Drug Metabolism and Disposition 1988; 17: 387–392
   Google Scholar
• Wrighton P., Brian W. R., Sari M. ‐A., Iwasaki M., Guengerich F. P., Ranay J. L., Molowa D. J., Branden V. Studies on the expression and the metabolic capabilities of human liver P4503A5 (HLp3)11. Molecular Pharmacology 1990; 38: 207–213
   PubMed Web of Science ®Google Scholar
• Yamano S., Tatsuno J., Gonzalez F. J. The CYP2A3 gene product catalyses coumarin 7‐hydroxylation in human liver microsomes. Biochemistry 1990; 29: 1322–1329
   PubMed Web of Science ®Google Scholar
• Yamazaki H., Oda Y., Funae Y., Imaoka S., Inui Y., Guengerich F. P., Shimada T. Participation of rat liver cytochrome P4502E1 in the activation of N‐nitrosodimethylamine and N‐nitrosodiethylamine to products genotoxic in an acetyltransferase overexpressing Salmonella typhimurium strain. Carcinogenesis 1992; 13: 979–985
   PubMed Web of Science ®Google Scholar
• Yamazoe Y., Ngai T. S., Kamataki T. Specifity of four forms of P450 in the metabolic activation of several aromatic amines and benzo(a)pyrene. Xenobiotica 1984; 14: 549–561
   PubMed Web of Science ®Google Scholar
• Yang C. S., Patten C. J., Ishizaki H., Yoo J. ‐S. H. Induction, purification and characterization of P4502E1. Methods in Enzymology 1991; 21–33
   Google Scholar
• Yang C. ‐S., Yoo J. S., Ishizaki H., Hang J. Cytochrome P4502E1: roles in nitrosamine metabolism and mechanism of regulation. Drug Metabolism Reviews 1990; 22: 147–159
   PubMed Web of Science ®Google Scholar
• Yashimori T., Murayama N., Yamazoe Y., Nogi Y., Fukasawa T., Kato R. Expression of a human P450IIC gene in yeast cells using galactose unducible expression system. Molecular Pharmacology 1989; 35: 443–449
   PubMedGoogle Scholar
• Yoo J. ‐S., Guengerich F. P., Yang C. S. Metabolism of N‐nitrosodiakylamines by human liver microsomes. Cancer Research 1988; 88: 1499–1504
   Google Scholar
• Yun C. ‐H., Shimada T., Guengerich F. P. Purification and characterization of a human liver microsomal cytochrome P450 2A6. Molecular Pharmacology 1991a; 40: 679–85
   PubMed Web of Science ®Google Scholar
• Yun C. ‐H., Shimada T., Guengerich F. P. Roles of cytochromes 2C11 and 3A enzymes in the 3'‐hydroxylation of benzo(a)pyrene. Cancer Research 1991b; 52: 1864–1874
   Google Scholar
• Zhou H. H., Anthony L. B., Wood A. J. J., Wilkinson G. R. Induction by rifampin of genetically determined 4‐hydroxylation of S‐mephenytoin in man. Clinical Pharmacology and Therapeutics 1985; 43: 135–142
   Google Scholar
• Wrighton P., Brian W. R., Sari M. ‐A., Iwasaki M., Guengerich F. P., Ranay J. L., Molowa D. J., Branden V. Studies on the expression and the metabolic capabilities of human liver P4503A5 (HLp3)11. Molecular Pharmacology 1990; 38: 207–213
   PubMed Web of Science ®Google Scholar
• Yamano S., Tatsuno J., Gonzalez F. J. The CYP2A3 gene product catalyses coumarin 7‐hydroxylation in human liver microsomes. Biochemistry 1990; 29: 1322–1329
   PubMed Web of Science ®Google Scholar
• Yamazaki H., Oda Y., Funae Y., Imaoka S., Inui Y., Guengerich F. P., Shimada T. Participation of rat liver cytochrome P4502E1 in the activation of N‐nitrosodimethylamine and N‐nitrosodiethylamine to products genotoxic in an acetyltransferase overexpressing Salmonella typhimurium strain. Carcinogenesis 1992; 13: 979–985
   PubMed Web of Science ®Google Scholar
• Yamazoe Y., Ngai T. S., Kamataki T. Specifity of four forms of P450 in the metabolic activation of several aromatic amines and benzo(a)pyrene. Xenobiotica 1984; 14: 549–561
   PubMed Web of Science ®Google Scholar
• Yang C. S., Patten C. J., Ishizaki H., Yoo J. ‐S. H. Induction, purification and characterization of P4502E1. Methods in Enzymology 1991; 21–33
   Google Scholar
• Yang C. ‐S., Yoo J. S., Ishizaki H., Hang J. Cytochrome P4502E1: roles in nitrosamine metabolism and mechanism of regulation. Drug Metabolism Reviews 1990; 22: 147–159
   PubMed Web of Science ®Google Scholar
• Yashimori T., Murayama N., Yamazoe Y., Nogi Y., Fukasawa T., Kato R. Expression of a human P450IIC gene in yeast cells using galactose unducible expression system. Molecular Pharmacology 1989; 35: 443–449
   PubMedGoogle Scholar
• Yoo J. ‐S., Guengerich F. P., Yang C. S. Metabolism of N‐nitrosodiakylamines by human liver microsomes. Cancer Research 1988; 88: 1499–1504
   Google Scholar
• Yun C. ‐H., Shimada T., Guengerich F. P. Purification and characterization of a human liver microsomal cytochrome P450 2A6. Molecular Pharmacology 1991a; 40: 679–85
   PubMed Web of Science ®Google Scholar
• Yun C. ‐H., Shimada T., Guengerich F. P. Roles of cytochromes 2C11 and 3A enzymes in the 3'‐hydroxylation of benzo(a)pyrene. Cancer Research 1991b; 52: 1864–1874
   Google Scholar
• Zhou H. H., Anthony L. B., Wood A. J. J., Wilkinson G. R. Induction by rifampin of genetically determined 4‐hydroxylation of S‐mephenytoin in man. Clinical Pharmacology and Therapeutics 1985; 43: 135–142
   Google Scholar